CD47: Regulation of cellular phagocytosis in cancer, inflammation & neurobiology

| October 11, 2017

article image
CD47 is a cell surface ‘don’t eat me’ signal that has been shown to be important in detection and evasion of cancer cells, inflammation, neuronal pruning and other path ophysiological processes. Blocking CD47 allows tumor cells to be recognized by phagocytes and this cell-cell interaction initiates a cascade of events resulting in tumor cell destruction. As such CD47 is an attractive target for the development of novel therapeutics.

Spotlight

Octopus Healthcare

We're not your typical healthcare business, we’re all about the long term partnership approach. As specialists in healthcare, we invest in and develop primary care centres, care homes, retirement villages, private hospitals and specialist schools, creating brilliant new environments to improve people’s health and wellbeing experience, for the better.

OTHER ARTICLES

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | April 3, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | April 3, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | April 3, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Spotlight

Octopus Healthcare

We're not your typical healthcare business, we’re all about the long term partnership approach. As specialists in healthcare, we invest in and develop primary care centres, care homes, retirement villages, private hospitals and specialist schools, creating brilliant new environments to improve people’s health and wellbeing experience, for the better.

Events